Discovery

Cubist pipeline building efforts are focused on opportunities that leverage the company's antiinfective and acute-care discovery, development, and commercialization expertise. Cubist's current research activities are focused on developing a therapy for use in treatment of hepatitis C (HCV) infections (the recently-acquired CB-183872* program), an antibiotic treatment for Clostridium difficile associated diarrhea (CDAD), and a new therapy for treatment of Gram-negative infections. Cubist also continues a limited program of Natural Products screening with the objective of generating novel antibiotic candidate(s).

* Formerly IB657 from Illumigen Biosciences.